Immuneering News and Activities

Immuneering is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Immuneering is a company listed under the stock ticker IMRX (US).

View the org chart displaying its 32 main executives

Most searched biographies at Immuneering

• Ben Zeskind, President, Chief Executive Officer and Director
• Bob Carpenter, Chair Emeritus
• Laurie Keating, Director

Popular executive movements at Immuneering

• Andrew Gengos will join the company as Chief Financial Officer on Jul. 16, 2026  (posted on June 16 2026).

Create your alert
to follow the executive moves at Immuneering.

Immuneering has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Immuneering

• 1-year survival nearly doubles in trial of pancreatic cancer therapy
• Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
• Pancreatic cancer treatment atebimetinib set for Phase 3 trial
• Immuneering’s pancreatic cancer pill continues to beat standard care, updated first-line data show
• Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year
• The MEK effect on cancer — a slow and steady approach to drug resistance
• Immuneering says MEK pill beats standard of care in first-line pancreatic cancer
• Immuneering Announces Participation in William Blair Biotech Focus Conference 2022 | Immuneering Corporation
• Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 | Immuneering Corporation
• Press Releases | Immuneering Corporation
• View more press releases Close

Social media about Immuneering

• Immuneering on Wikipedia, Google News & Yahoo Finance
• Immuneering on LinkedIn, X (Twitter) & YouTube